Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 130 biologics in R&D and 50 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular, Renal and Metabolism

Phase 1

Phase 1

  • MEDI6570 cardiovascular disease
  • MEDI7219 type-2 diabetes

Phase 2

Phase 2

  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease
  • cotadutide (MEDI0382) type-2 diabetes/obesity

Phase 3

Phase 3

LCM Projects

LCM Projects

Oncology

Phase 1

Phase 1

  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + chemotherapy 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • MEDI2228 multiple myeloma
  • MEDI3726 prostate cancer
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • oleclumab + Tagrisso EGFRm NSCLC

Phase 2

Phase 2

  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + Imfinzi MEDIOLA ovarian cancer, breast cancer, gastic cancer and small-cell lung cancer

Phase 3

Phase 3

  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + CRT ADRIATIC LD-SCLC
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi + tremelimumab + chemo POSEIDON 1st-line non-small cell lung cancer
  • Lumoxiti PLAIT 3rd-line hairy cell leukaemia

LCM Projects

LCM Projects

  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi solid tumours
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage III) NSCLC
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellar carcinoma

Respiratory

Phase 1

Phase 1

  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • tezepelumab atopic dermatitis

Phase 3

Phase 3

  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE severe uncontrolled asthma
  • tezepelumab NAVIGATOR SOURCE severe, uncontrolled asthma

LCM Projects

LCM Projects

  • Fasenra OSTRO nasal polyposis
  • Fasenra TERRANOVA GALATHEA chronic obstructive pulmonary disease

Other

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1341 parkinson's disease
  • MEDI1814 Alzheimer’s disease

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI7352 osteoarthritis pain / painful diabetic neuropathy
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • prezalumab primary Sjögren’s syndrome
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

Terminations



AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.